Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 2.05
WAT's Cash-to-Debt is ranked higher than
61% of the 261 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.52 vs. WAT: 2.05 )
Ranked among companies with meaningful Cash-to-Debt only.
WAT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 1.17 Max: 336.71
Current: 2.05
0
336.71
Equity-to-Asset 0.47
WAT's Equity-to-Asset is ranked lower than
62% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. WAT: 0.47 )
Ranked among companies with meaningful Equity-to-Asset only.
WAT' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.05  Med: 0.45 Max: 0.7
Current: 0.47
-0.05
0.7
Debt-to-Equity 0.59
WAT's Debt-to-Equity is ranked lower than
72% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.36 vs. WAT: 0.59 )
Ranked among companies with meaningful Debt-to-Equity only.
WAT' s Debt-to-Equity Range Over the Past 10 Years
Min: -27.63  Med: 0.81 Max: 5.91
Current: 0.59
-27.63
5.91
Debt-to-EBITDA 1.49
WAT's Debt-to-EBITDA is ranked lower than
53% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.77 vs. WAT: 1.49 )
Ranked among companies with meaningful Debt-to-EBITDA only.
WAT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.13  Med: 2.11 Max: 2.5
Current: 1.49
1.13
2.5
Interest Coverage 11.86
WAT's Interest Coverage is ranked lower than
60% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.01 vs. WAT: 11.86 )
Ranked among companies with meaningful Interest Coverage only.
WAT' s Interest Coverage Range Over the Past 10 Years
Min: 10.12  Med: 16.44 Max: 35.92
Current: 11.86
10.12
35.92
Piotroski F-Score: 7
Altman Z-Score: 7.37
Beneish M-Score: -3.03
WACC vs ROIC
10.55%
2.46%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 29.35
WAT's Operating Margin % is ranked higher than
95% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.59 vs. WAT: 29.35 )
Ranked among companies with meaningful Operating Margin % only.
WAT' s Operating Margin % Range Over the Past 10 Years
Min: 24.74  Med: 27.56 Max: 29.35
Current: 29.35
24.74
29.35
Net Margin % 1.14
WAT's Net Margin % is ranked higher than
51% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.48 vs. WAT: 1.14 )
Ranked among companies with meaningful Net Margin % only.
WAT' s Net Margin % Range Over the Past 10 Years
Min: 0.88  Med: 23.1 Max: 25.03
Current: 1.14
0.88
25.03
ROE % 1.12
WAT's ROE % is ranked higher than
52% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.75 vs. WAT: 1.12 )
Ranked among companies with meaningful ROE % only.
WAT' s ROE % Range Over the Past 10 Years
Min: 0.9  Med: 31.06 Max: 51.72
Current: 1.12
0.9
51.72
ROA % 0.54
WAT's ROA % is ranked higher than
55% of the 262 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.54 vs. WAT: 0.54 )
Ranked among companies with meaningful ROA % only.
WAT' s ROA % Range Over the Past 10 Years
Min: 0.41  Med: 14.5 Max: 18.41
Current: 0.54
0.41
18.41
ROC (Joel Greenblatt) % 100.21
WAT's ROC (Joel Greenblatt) % is ranked higher than
95% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -9.57 vs. WAT: 100.21 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
WAT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 72.34  Med: 85.19 Max: 100.21
Current: 100.21
72.34
100.21
3-Year Revenue Growth Rate 7.00
WAT's 3-Year Revenue Growth Rate is ranked higher than
63% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. WAT: 7.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
WAT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 5.2  Med: 8.75 Max: 19.5
Current: 7
5.2
19.5
3-Year EBITDA Growth Rate 11.10
WAT's 3-Year EBITDA Growth Rate is ranked higher than
60% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. WAT: 11.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
WAT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -1.1  Med: 11.75 Max: 51.6
Current: 11.1
-1.1
51.6
3-Year EPS without NRI Growth Rate -63.30
WAT's 3-Year EPS without NRI Growth Rate is ranked lower than
90% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. WAT: -63.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
WAT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 13.2 Max: 59.5
Current: -63.3
0
59.5
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» WAT's 30-Y Financials

Financials (Next Earnings Date: 2018-07-25)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

WAT Guru Trades in Q2 2017

Lee Ainslie 21,580 sh (New)
Pioneer Investments 37,476 sh (New)
Jim Simons 526,400 sh (+214.46%)
Ruane Cunniff 1,788,992 sh (+7.18%)
Paul Tudor Jones Sold Out
Joel Greenblatt 38,831 sh (-4.66%)
PRIMECAP Management 365,007 sh (-16.31%)
» More
Q3 2017

WAT Guru Trades in Q3 2017

Ray Dalio 9,297 sh (New)
Joel Greenblatt 78,185 sh (+101.35%)
Jim Simons 898,100 sh (+70.61%)
Lee Ainslie 26,880 sh (+24.56%)
Steven Cohen 100,000 sh (unchged)
PRIMECAP Management 344,687 sh (-5.57%)
Pioneer Investments 34,304 sh (-8.46%)
Ruane Cunniff 1,142,182 sh (-36.15%)
» More
Q4 2017

WAT Guru Trades in Q4 2017

Pioneer Investments 157,768 sh (+359.91%)
Lee Ainslie 42,930 sh (+59.71%)
Jim Simons 1,429,049 sh (+59.12%)
Ray Dalio Sold Out
Ruane Cunniff 1,135,909 sh (-0.55%)
PRIMECAP Management 336,377 sh (-2.41%)
Joel Greenblatt 72,365 sh (-7.44%)
» More
Q1 2018

WAT Guru Trades in Q1 2018

Ron Baron 168,468 sh (New)
Ray Dalio 8,993 sh (New)
Paul Tudor Jones 4,508 sh (New)
Joel Greenblatt 116,381 sh (+60.82%)
Lee Ainslie 55,500 sh (+29.28%)
PRIMECAP Management 332,257 sh (-1.22%)
Pioneer Investments 154,364 sh (-2.16%)
Jim Simons 1,264,800 sh (-11.49%)
Ruane Cunniff 10,455 sh (-99.08%)
» More
» Details

Insider Trades

Latest Guru Trades with WAT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2018-03-31 New Buy0.15%$191.79 - $218.7 $ 193.87-6%168,468
Joel Greenblatt 2018-03-31 Add 60.82%0.12%$191.79 - $218.7 $ 193.87-6%116,381
Ruane Cunniff 2018-03-31 Reduce -99.08%1.78%$191.79 - $218.7 $ 193.87-6%10,455
Ruane Cunniff 2017-12-31 Reduce -0.55%0.01%$180.92 - $200.27 $ 193.870%1,135,909
Joel Greenblatt 2017-12-31 Reduce -7.44%0.02%$180.92 - $200.27 $ 193.870%72,365
Ruane Cunniff 2017-09-30 Reduce -36.15%1.1%$172.58 - $190 $ 193.877%1,142,182
Joel Greenblatt 2017-09-30 Add 101.35%0.11%$172.58 - $190 $ 193.877%78,185
Ruane Cunniff 2017-06-30 Add 7.18%0.2%$154.83 - $186.33 $ 193.8712%1,788,992
Joel Greenblatt 2017-06-30 Reduce -4.66%$154.83 - $186.33 $ 193.8712%38,831
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 8071
Compare:NYSE:MTD, NYSE:RMD, TSE:7733, OCSE:COLO B, NAS:XRAY, NYSE:COO, XSWX:STMN, NAS:HOLX, TSE:4543, NYSE:STE, SZSE:002294, NYSE:WST, NYSE:HRC, NAS:ICUI, NAS:PODD, NYSE:CMD, TSE:7747, NYSE:HAE, MIL:AMP, OSTO:LIFCO B » details
Traded in other countries:WAZ.Germany,
Headquarter Location:USA
Waters Corp is an analytical instrument manufacturer. It designs, manufactures, sells and services liquid chromatography, ultra performance liquid chromatography & mass spectrometry instrument systems & support products.

Waters provides analytical instruments for pharmaceutical, biochemical, and industrial customers. Roughly half of sales are attributable to instruments, which include liquid chromatography and mass spectrometry platforms, as well as thermal analysis tools. Consumables and services account for the remainder of Waters' sales.

Top Ranked Articles about Waters Corp

Ron Baron’s Top 5 New Buys of the 1st Quarter Guru invests in several newly public companies
Ron Baron (Trades, Portfolio), leader of New York-based Baron Capital Management, released his first-quarter portfolio this week, listing 58 new positions. Read more...
Factors of Influence in 2018, Key Indicators and Opportunity within Rowan Companies, Waters, Ball, Arconic, Sears, and Cheniere Energy — New Research Emphasizes Economic Growth
5 Stocks to Watch Wednesday Comcast, Waters Corporation and Verizon high, Texas Instruments and Procter & Gamble down
In Wednesday premarket trading, Comcast Corp. (NASDAQ:CMCSA)’s stock traded higher as the company posted its financial results for the fourth quarter of its fiscal 2017. For the quarter, the company reported annual net sales growth of 4.3% to $21.92 billion, while its profit advanced to 49 cents per share. The results exceeded the analysts’ estimates by 2 cents in per-share earnings and $100 million in revenue. Read more...
New Research Coverage Highlights Cigna, Thermo Fisher Scientific, Raytheon, W. W. Grainger, Waters, and Cummins – Consolidated Revenues, Company Growth, and Expectations for 2018
Faruqi & Faruqi, LLP is Investigating Waters Corporation (WAT) on Behalf of its Shareholders

Ratios

vs
industry
vs
history
PE Ratio 646.23
WAT's PE Ratio is ranked lower than
99.99% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.00 vs. WAT: 646.23 )
Ranked among companies with meaningful PE Ratio only.
WAT' s PE Ratio Range Over the Past 10 Years
Min: 9.64  Med: 20.93 Max: 1038.76
Current: 646.23
9.64
1038.76
Forward PE Ratio 23.81
WAT's Forward PE Ratio is ranked higher than
50% of the 40 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. WAT: 23.81 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 646.23
WAT's PE Ratio without NRI is ranked lower than
99.99% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.56 vs. WAT: 646.23 )
Ranked among companies with meaningful PE Ratio without NRI only.
WAT' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.64  Med: 20.93 Max: 1038.76
Current: 646.23
9.64
1038.76
Price-to-Owner-Earnings 26.48
WAT's Price-to-Owner-Earnings is ranked higher than
54% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.75 vs. WAT: 26.48 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
WAT' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.12  Med: 23.02 Max: 33.41
Current: 26.48
10.12
33.41
PB Ratio 7.17
WAT's PB Ratio is ranked lower than
65% of the 245 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.02 vs. WAT: 7.17 )
Ranked among companies with meaningful PB Ratio only.
WAT' s PB Ratio Range Over the Past 10 Years
Min: 4.38  Med: 5.71 Max: 17.2
Current: 7.17
4.38
17.2
PS Ratio 6.65
WAT's PS Ratio is ranked lower than
67% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.81 vs. WAT: 6.65 )
Ranked among companies with meaningful PS Ratio only.
WAT' s PS Ratio Range Over the Past 10 Years
Min: 2.05  Med: 4.65 Max: 7.62
Current: 6.65
2.05
7.62
Price-to-Free-Cash-Flow 25.52
WAT's Price-to-Free-Cash-Flow is ranked higher than
55% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.22 vs. WAT: 25.52 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
WAT' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.66  Med: 22.29 Max: 30.04
Current: 25.52
9.66
30.04
Price-to-Operating-Cash-Flow 22.27
WAT's Price-to-Operating-Cash-Flow is ranked lower than
57% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.94 vs. WAT: 22.27 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
WAT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.82  Med: 17.96 Max: 25.21
Current: 22.27
7.82
25.21
EV-to-EBIT 19.13
WAT's EV-to-EBIT is ranked higher than
58% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.06 vs. WAT: 19.13 )
Ranked among companies with meaningful EV-to-EBIT only.
WAT' s EV-to-EBIT Range Over the Past 10 Years
Min: 8  Med: 16.6 Max: 25.2
Current: 19.13
8
25.2
EV-to-EBITDA 16.58
WAT's EV-to-EBITDA is ranked higher than
50% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.75 vs. WAT: 16.58 )
Ranked among companies with meaningful EV-to-EBITDA only.
WAT' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.9  Med: 14.3 Max: 21.8
Current: 16.58
6.9
21.8
EV-to-Revenue 5.92
WAT's EV-to-Revenue is ranked lower than
60% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.24 vs. WAT: 5.92 )
Ranked among companies with meaningful EV-to-Revenue only.
WAT' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.1  Med: 4.4 Max: 7
Current: 5.92
2.1
7
PEG Ratio 71.48
WAT's PEG Ratio is ranked lower than
99.99% of the 48 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.26 vs. WAT: 71.48 )
Ranked among companies with meaningful PEG Ratio only.
WAT' s PEG Ratio Range Over the Past 10 Years
Min: 0.57  Med: 1.63 Max: 114.53
Current: 71.48
0.57
114.53
Shiller PE Ratio 40.65
WAT's Shiller PE Ratio is ranked lower than
59% of the 39 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.49 vs. WAT: 40.65 )
Ranked among companies with meaningful Shiller PE Ratio only.
WAT' s Shiller PE Ratio Range Over the Past 10 Years
Min: 16.64  Med: 30 Max: 51.34
Current: 40.65
16.64
51.34
Current Ratio 6.44
WAT's Current Ratio is ranked higher than
91% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.58 vs. WAT: 6.44 )
Ranked among companies with meaningful Current Ratio only.
WAT' s Current Ratio Range Over the Past 10 Years
Min: 1.19  Med: 2 Max: 7.04
Current: 6.44
1.19
7.04
Quick Ratio 5.87
WAT's Quick Ratio is ranked higher than
92% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. WAT: 5.87 )
Ranked among companies with meaningful Quick Ratio only.
WAT' s Quick Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.55 Max: 6.6
Current: 5.87
0.74
6.6
Days Inventory 109.41
WAT's Days Inventory is ranked higher than
65% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.76 vs. WAT: 109.41 )
Ranked among companies with meaningful Days Inventory only.
WAT' s Days Inventory Range Over the Past 10 Years
Min: 96.3  Med: 107.8 Max: 110.42
Current: 109.41
96.3
110.42
Days Sales Outstanding 78.39
WAT's Days Sales Outstanding is ranked lower than
62% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.51 vs. WAT: 78.39 )
Ranked among companies with meaningful Days Sales Outstanding only.
WAT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 67.61  Med: 79.83 Max: 84.38
Current: 78.39
67.61
84.38
Days Payable 26.93
WAT's Days Payable is ranked lower than
70% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. WAT: 26.93 )
Ranked among companies with meaningful Days Payable only.
WAT' s Days Payable Range Over the Past 10 Years
Min: 24.87  Med: 28.41 Max: 35.98
Current: 26.93
24.87
35.98

Buy Back

vs
industry
vs
history
5-Year Yield-on-Cost % 0.10
WAT's 5-Year Yield-on-Cost % is ranked lower than
99.99% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.41 vs. WAT: 0.10 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
WAT' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: 0.1
3-Year Average Share Buyback Ratio 1.60
WAT's 3-Year Average Share Buyback Ratio is ranked higher than
94% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.90 vs. WAT: 1.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
WAT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -3.1  Med: 2.35 Max: 6.3
Current: 1.6
-3.1
6.3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 85.78
WAT's Price-to-Net-Cash is ranked higher than
52% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.60 vs. WAT: 85.78 )
Ranked among companies with meaningful Price-to-Net-Cash only.
WAT' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 19.71  Med: 57.76 Max: 401.52
Current: 85.78
19.71
401.52
Price-to-Net-Current-Asset-Value 14.27
WAT's Price-to-Net-Current-Asset-Value is ranked lower than
63% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.88 vs. WAT: 14.27 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
WAT' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 8.43  Med: 15.4 Max: 310.33
Current: 14.27
8.43
310.33
Price-to-Tangible-Book 9.98
WAT's Price-to-Tangible-Book is ranked lower than
65% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.46 vs. WAT: 9.98 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
WAT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 6.17  Med: 11.07 Max: 1545.29
Current: 9.98
6.17
1545.29
Price-to-Intrinsic-Value-Projected-FCF 2.14
WAT's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
53% of the 75 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. WAT: 2.14 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
WAT' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.87  Med: 1.66 Max: 10.23
Current: 2.14
0.87
10.23
Price-to-Intrinsic-Value-DCF (Earnings Based) 60.40
WAT's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
99.99% of the 17 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.86 vs. WAT: 60.40 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
WAT' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.5  Med: 1.2 Max: 85.86
Current: 60.4
0.5
85.86
Price-to-Median-PS-Value 1.43
WAT's Price-to-Median-PS-Value is ranked lower than
62% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. WAT: 1.43 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
WAT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.27  Med: 0.96 Max: 3.34
Current: 1.43
0.27
3.34
Price-to-Peter-Lynch-Fair-Value 67.08
WAT's Price-to-Peter-Lynch-Fair-Value is ranked lower than
99.99% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.01 vs. WAT: 67.08 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
WAT' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.67  Med: 1.61 Max: 101.68
Current: 67.08
0.67
101.68
Price-to-Graham-Number 16.93
WAT's Price-to-Graham-Number is ranked lower than
99.99% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.98 vs. WAT: 16.93 )
Ranked among companies with meaningful Price-to-Graham-Number only.
WAT' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 2.34  Med: 3.34 Max: 49.57
Current: 16.93
2.34
49.57
Earnings Yield (Greenblatt) % 5.23
WAT's Earnings Yield (Greenblatt) % is ranked higher than
81% of the 265 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.98 vs. WAT: 5.23 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
WAT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4  Med: 6 Max: 12.6
Current: 5.23
4
12.6
Forward Rate of Return (Yacktman) % 12.68
WAT's Forward Rate of Return (Yacktman) % is ranked lower than
51% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.45 vs. WAT: 12.68 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
WAT' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 9.2  Med: 15.5 Max: 24.5
Current: 12.68
9.2
24.5

More Statistics

Revenue (TTM) (Mil) $2,341.78
EPS (TTM) $ 0.30
Beta1.47
Volatility19.80%
52-Week Range $171.32 - 220.20
Shares Outstanding (Mil)78.34

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 2,451 2,580 2,707
EBIT (Mil $) 727 777
EBITDA (Mil $) 845 895 963
EPS ($) 7.64 8.26 9.91
EPS without NRI ($) 7.64 8.26 9.91
EPS Growth Rate
(Future 3Y To 5Y Estimate)
7.06%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}